Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$4.89 USD
-0.14 (-2.78%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.00 +0.11 (2.25%) 5:36 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLN 4.89 -0.14(-2.78%)
Will SLN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Other News for SLN
SLN forms MACD Bullish Signal Line Cross on September 19
Directional Movement Crossover Bullish appears for SLN after 3.3% move
Stochastic Buy Signal appears for SLN after 2.54% move
Lower Bollinger Band Walk appears for SLN after 4.88% move
Silence Therapeutics (SLN) Receives Reiterated Buy Rating from HC Wainwright | SLN Stock News